SeqLL Inc. Common stock is a diagnostics & research business based in the US. SeqLL IncCommon stock shares (SQL) are listed on the NASDAQ and all prices are listed in US Dollars. SeqLL IncCommon stock employs 8 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $3.60 |
|---|---|
| 52-week range | $3.30 - $5.80 |
| 50-day moving average | $3.91 |
| 200-day moving average | $3.92 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.41 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.6 from 2021-10-18
| 1 week (2021-10-13) | 1.12% |
|---|---|
| 1 month (2021-09-20) | -5.01% |
| 3 months (2021-07-16) | N/A |
| 6 months (2021-04-16) | N/A |
| 1 year (2020-10-16) | N/A |
|---|---|
| 2 years (2019-10-16) | N/A |
| 3 years (2018-10-16) | N/A |
| 5 years (2016-10-16) | N/A |
| Revenue TTM | $327,271 |
|---|---|
| Gross profit TTM | $158,692 |
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | $40.5 million |
TTM: trailing 12 months
There are currently 89,746 SeqLL IncCommon stock shares held short by investors – that's known as SeqLL IncCommon stock's "short interest". This figure is 48.7% down from 175,027 last month.
There are a few different ways that this level of interest in shorting SeqLL IncCommon stock shares can be evaluated.
SeqLL IncCommon stock's "short interest ratio" (SIR) is the quantity of SeqLL IncCommon stock shares currently shorted divided by the average quantity of SeqLL IncCommon stock shares traded daily (recently around 1.1 million). SeqLL IncCommon stock's SIR currently stands at 0.08. In other words for every 100,000 SeqLL IncCommon stock shares traded daily on the market, roughly 80 shares are currently held short.
To gain some more context, you can compare SeqLL IncCommon stock's short interest ratio against those of similar companies.
However SeqLL IncCommon stock's short interest can also be evaluated against the total number of SeqLL IncCommon stock shares, or, against the total number of tradable SeqLL IncCommon stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SeqLL IncCommon stock's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 SeqLL IncCommon stock shares in existence, roughly 10 shares are currently held short) or 0.0504% of the tradable shares (for every 100,000 tradable SeqLL IncCommon stock shares, roughly 50 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against SeqLL IncCommon stock.
Find out more about how you can short SeqLL IncCommon stock stock.
We're not expecting SeqLL IncCommon stock to pay a dividend over the next 12 months.
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It designs, develops, and manufactures genetic analysis technologies; and offers true single molecule sequencing (tSMS) platform that assists researchers to develop research, diagnostics, and therapeutics applications. The company also provides RNA sequencing services and instruments, which include Direct RNA Sequencing, a genetic testing and mapping service that captures polyadenylated RNA directly without conversion to cDNA; tSMS formalin fixed paraffin embedded (FFPE) service to analyze damaged or fragmented nucleic acids from formalin fixed paraffin embedded samples and other sources; micro RNA sequencing; and custom sequencing, and mapping and testing services, as well as gene expression studies, FFPE RNA Sequencing, biomarker discovery, fusion detection, rare mutation detection, transcriptome profiling, and cap analysis gene expression services. In addition, it offers DNA sequencing services and instruments, such as shotgun DNA sequencing, direct capture sequencing, cell free DNA sequencing, FFPE DNA sequencing, ancient DNA sequencing, and targeted sequencing, as well as microbiome studies, biomarker discovery, and tumor profiling services. Further, the company provides bioinformatics services comprising data processing, biomarkers research, pathway analysis, and gene expression analysis services, as well as undertakes various custom projects. It has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.